Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-107 in treatment-resistant major depressive disorder
ACTRN12618001042235Phase 2Completed
- Sponsor
- Douglas Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of R107 in major depressive disorder (MDD) (6 arms), sponsored by Douglas Pharmaceuticals. Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale total score. Started May 2019; status: completed.
02
Drugs
R107
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12618001042235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001042235.